Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan | Zendy

Yoshiyuki Furumatsu | Zendy; Yasuyuki Nagasawa | Zendy; Takayuki Hamano | Zendy; Hirotsugu Iwatani | Zendy; K. IIO | Zendy; T. Shoji | Zendy; Tomonobu Ito | Zendy; Yoshiharu Tsubakihara | Zendy; Enyu Imai | Zendy

Open Access

Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan

Author(s) -

Yoshiyuki Furumatsu,

Yasuyuki Nagasawa,

Takayuki Hamano,

Hirotsugu Iwatani,

K. IIO,

T. Shoji,

Tomonobu Ito,

Yoshiharu Tsubakihara,

Enyu Imai

Publication year - 2007

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfm705

Subject(s) - medicine , incidence (geometry) , erythropoietin , end stage renal disease , dialysis , disease , kidney disease , hemodialysis , stage (stratigraphy) , intensive care medicine , urology , physics , optics , paleontology , biology

Erythropoietin (EPO) has been reported to slow the decline of renal function in predialysis chronic kidney disease (CKD) patients. On the contrary, in the recent large-scale randomized controlled trial (RCT), CREATE and CHOIR, which aimed to keep a higher haemoglobin (Hb) level than former trials, the renoprotective effect of EPO was not observed. Today, the renoprotective effect of EPO has become controversial. In order to test the hypothesis that the usage of EPO in predialysis CKD patients may ameliorate the progression of renal disease, we conducted a macro-level observational study dealing with all Japanese predialysis CKD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research